Aligos Therapeutics ALGS 深 沪
等待开盘 09-10 09:30:00 美东时间
11.22
+0.110
+0.99%
华盛通- 最 高11.2718
- 今 开10.89
- 成交量 2.75万股
- 最 低 10.66
- 昨 收 11.11
- 总市值 6860.81万
- 52周最高 46.80
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 3.76
- 委 比 0.00%
- 总股本 611.48万
- 历史最高 937.75
- 量 比 0.65
- 振 幅 5.51%
- 历史最低 3.76
- 每 手 1
- 风险率 10.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
Aligos Therapeutics announced six presentations, including three oral, at the 2025 International HBV Meeting in Berlin. The company highlighted advancements in therapies for liver and viral diseases, focusing on ALG-000184's effects on HBV cccDNA reduction and a novel ASO approach for HDV cure. CEO Lawrence Blatt emphasized innovation in HBV treatment and the expansion of their pipeline with the ASO program targeting HDV, which uniquely destroys ...
09-03 20:05
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aligos Therapeutics announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 8-10, 2025. The presentation can be viewed on-demand via the company's website, with a replay available for 30 days. Aligos focuses on developing best-in-class therapies for liver and viral diseases, targeting unmet medical needs such as chronic hepatitis B, metabolic-associated steatohepatitis, and coronaviruses...
09-02 20:05
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
Aligos Therapeutics appointed Ramón Polo, PharmD, PhD, MBA, as Senior Vice President and Head of Global Regulatory Affairs. With extensive experience in regulatory affairs, including leading global strategies at Shionogi and Johnson & Johnson, Polo will support the development of ALG-000184, currently in Phase 2 B-SUPREME study for liver and viral diseases. His expertise is expected to guide Aligos through pivotal stages of its pipeline.
08-20 12:30
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
Aligos Therapeutics has initiated dosing in its Phase 2 B-SUPREME study for ALG-000184, a potential best-in-class therapy for chronic hepatitis B virus (HBV) infection. The randomized, double-blind study will assess ALG-000184's safety and efficacy in over 200 adult subjects over 48 weeks. Neutral antiviral activity and safety data from Phase 1 trials support promising potential. Aligos expects interim results in 2026 and full data in 2027. ALG-0...
08-13 12:30
Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
In the last three months, 6 analysts have published ratings on Mirum Pharmaceut...
08-09 02:02
Aligos Therapeutics Q2 EPS $(1.53) Beats $(2.36) Estimate, Sales $965.00K Beat $433.33K Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(2.36) by 35.25 percent. This is a 304 percent decrease over earnings of $0.75 per share from
08-07 04:14
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Aligos Therapeutics reported second-quarter 2025 progress, highlighting the initiation of the Phase 2 B-SUPREME study for ALG-000184, a potential best-in-class treatment for chronic hepatitis B. The company presented promising 96-week Phase 1 data, showing sustained viral suppression and safety. ALG-055009 demonstrated efficacy in reducing liver fat and atherogenic lipids in metabolic dysfunction-associated steatohepatitis. ALG-097558 clinical tr...
08-06 20:05
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
Aligos Therapeutics (NASDAQ: ALGS), a clinical-stage biotech company focused on treating liver and viral diseases, announces it will report its Q2 2025 financial results on August 6 after U.S. markets close. The company specializes in developing best-in-class therapies for chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, and coronaviruses. Forward-looking statements are included, subject to risks inherent in drug development...
07-30 20:05
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
Aligos Therapeutics has appointed Kieron Wesson, PhD, as Vice President and Head of Chemistry, Manufacturing, and Controls (CMC). Wesson brings over 20 years of experience in pharmaceutical development and will oversee all CMC-related matters, including the upcoming Phase 2 study of ALG-000184. Previously, he held leadership roles at Kezar Life Sciences, AN2 Therapeutics, and Anacor Pharmaceuticals. Aligos, a clinical-stage biotech company specia...
06-18 12:00
